I agree that this site is using cookies. You can find further informations here.
X
Lemery, Steven
44  results:
Search for persons X
?
1

Association between antibiotics and adverse oncological out..:

Pinato, David J. ; Li, Xiaoxue ; Mishra-Kalyani, Pallavi...
JHEP Reports.  5 (2023)  6 - p. 100747 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Approvals in 2021: dangling Accelerated Approvals, drug dos..:

Lemery, Steven ; Pazdur, Richard
Nature Reviews Clinical Oncology.  19 (2022)  4 - p. 217-218 , 2022
Link: https://doi.org/10.1038/..
 
?
3

Development of Tissue-Agnostic Treatments for Patients with..:

Lemery, Steven ; Fashoyin-Aje, Lola ; Marcus, Leigh...
Annual Review of Cancer Biology.  6 (2022)  1 - p. 147-165 , 2022
Link: https://doi.org/10.1146/..
 
?
4

FDA Approval Summary: Nivolumab Plus Ipilimumab for the Tre..:

Saung, May Tun ; Pelosof, Lorraine ; Casak, Sandra...
The Oncologist.  26 (2021)  9 - p. 797-806 , 2021
Link: https://doi.org/10.1002/..
 
?
5

Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: Fro..:

Chang, Elaine ; Pelosof, Lorraine ; Lemery, Steven...
The Oncologist.  26 (2021)  10 - p. e1786-e1799 , 2021
Link: https://doi.org/10.1002/..
 
?
6

Benefit–Risk Summary of Nivolumab for the Treatment of Pati..:

Pelosof, Lorraine ; Saung, May Tun ; Donoghue, Martha...
The Oncologist.  26 (2021)  4 - p. 318-324 , 2021
Link: https://doi.org/10.1002/..
 
?
7

FDA Accelerated Approval of Pembrolizumab for Recurrent Loc..:

Bradford, Diana ; Demko, Suzanne ; Jin, Susan...
The Oncologist.  25 (2020)  7 - p. e1077-e1082 , 2020
Link: https://doi.org/10.1634/..
 
?
8

Immune Response Evaluation and Treatment with Immune Checkp..:

Mushti, Sirisha L. ; Mulkey, Flora ; Tang, Shenghui...
Current Oncology Reports.  22 (2020)  11 - p. , 2020
Link: https://doi.org/10.1007/..
 
?
9

Benefit-Risk Summary of Regorafenib for the Treatment of Pa..:

Pelosof, Lorraine ; Lemery, Steven ; Casak, Sandra...
The Oncologist.  23 (2018)  4 - p. 496-500 , 2018
Link: https://doi.org/10.1634/..
 
?
10

Informing the Tolerability of Cancer Treatments Using Patie..:

Kluetz, Paul G. ; Kanapuru, Bindu ; Lemery, Steven...
Value in Health.  21 (2018)  6 - p. 742-747 , 2018
Link: https://doi.org/10.1016/..
 
?
11

Considerations for Developing Targeted Therapies in Low‐Fre..:

Schuck, Robert N. ; Woodcock, Janet ; Zineh, Issam...
Clinical Pharmacology & Therapeutics.  104 (2018)  2 - p. 282-289 , 2018
Link: https://doi.org/10.1002/..
 
?
12

Overview of FDA's Expanded Access Program for Investigation..:

Jarow, Jonathan P. ; Lurie, Peter ; Ikenberry, Sarah Crowley.
Therapeutic Innovation & Regulatory Science.  51 (2017)  2 - p. 177-179 , 2017
Link: https://doi.org/10.1177/..
 
?
13

Ten-Year Experience for the Center for Drug Evaluation and ..:

Jarow, Jonathan P. ; Lemery, Steven ; Bugin, Kevin.
Therapeutic Innovation & Regulatory Science.  51 (2017)  2 - p. 246-249 , 2017
Link: https://doi.org/10.1177/..
 
?
14

Expanded Access of Investigational Drugs: The Experience of..:

Jarow, Jonathan P. ; Lemery, Steven ; Bugin, Kevin..
Therapeutic Innovation & Regulatory Science.  50 (2016)  6 - p. 705-709 , 2016
Link: https://doi.org/10.1177/..
 
?
15

Benefit-Risk Summary of Crizotinib for the Treatment of Pat..:

Kazandjian, Dickran ; Blumenthal, Gideon M. ; Luo, Lola...
The Oncologist.  21 (2016)  8 - p. 974-980 , 2016
Link: https://doi.org/10.1634/..
 
1-15